As of May 15, 2019, thirteen of fifteen sites are officially screening for our FDA-regulated Phase 3 clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Newly screening …
As of April 3, 2019, ten of fifteen sites are officially screening for our Phase 3 clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Study participants will be administered …
As of March 6, 2019, nine of fifteen sites are officially screening for our Phase 3 clinical trial of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD). Study volunteers will be administered …
On February 5, 2019, a MAPS-sponsored Phase 3 study site for MDMA-assisted psychotherapy for PTSD was initiated in Be’er Ya’akov, Israel. Led by Principal Investigator Jana Yakirevitch, M.D., this …
On February 3, 2019, the Israeli Ministry of Health announced the approval of compassionate use for MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD), which will allow 50 patients to …
This month, our Phase 3 multi-site study of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) is continuing to open sites for screening. Eight sites are open for screening at this time. …
This month, MAPS study sites in New Orleans, Louisiana, Charleston, South Carolina, Fort Collins, and Boulder, Colorado received a shipment of pharmaceutical-grade MDMA, made under current Good Manufacturing …
Our FDA-regulated Phase 3 clinical trials of MDMA-assisted psychotherapy for PTSD have officially launched. These trials are taking place at 14 locations across the United States, Canada, and Israel. On …
MAPS-sponsored researchers have completed study initiation visits for FDA-regulated Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder (PTSD) at five United States locations: …
As summer comes to a close, we will begin the process of screening applications and enrolling participants for FDA-regulated Phase 3 trials of MDMA-assisted psychotherapy for posttraumatic stress disorder …
On June 12, 2018, MAPS had a successful meeting in London, United Kingdom, with the Scientific Advice Working Party (SAWP) of the European Medicines Agency (EMA). The discussion focused on scientific advice …
A Phase 3 Program of MDMA-Assisted Therapy for the Treatment of Severe Posttraumatic Stress Disorder (PTSD) Two Trials: MAPP1 and MAPP2 Study Sponsor: MAPS, a 501(c)(3) non-profit research organization …
